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Introduction
The appearance of second primary malignancy (SPM)
is a crucial problem in treating patients with head 
and neck squamous cell carcinoma (HNSCC) and 
has a negative impact on survival.1–4 As a result of 
carcinogen exposure, patients with HNSCC face a sig-
nificantly higher risk of developing a new malignancy
than the general population.4,5 Depending on the 
primary site and follow-up duration, the incidence of
SPM in HNSCC patients varies between 14% and
47%.1–5 Nonetheless, the pattern of SPM differs from
person to person, and the follow-up program should
be adjusted individually.
The purpose of this study was to identify the inci-
dence, patterns, and survival of SPM in patients with
squamous cell carcinoma of the tongue (TSCC) and
larynx (LSCC), and to explore the potential associa-
tion between the index tumor and SPM, in order to
guide appropriate surveillance protocol, treatment, and
outcome prediction.
Methods
We retrospectively reviewed 538 previously untreated
patients, including 146 TSCC and 392 LSCC patients,
who underwent surgery for curative intent at the
Department of Otolaryngology, Taipei Veterans General
Hospital, between January 1990 and December 2000.
TSCC patients treated at the Department of Dentistry
were excluded because of a different management policy.
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At the time of data collection, all of the patients had
been followed for a minimum of 5 years after surgery.
Patient characteristics are listed in Table 1.
The index tumor was defined as the first diagnosed
tumor and was re-staged according to the TNM stag-
ing system of the 2002 American Joint Committee on
Cancer. All of the patients had biopsy-proven SCC and
underwent comprehensive tumor surveys. Seventy per-
cent of TSCC and 53% of LSCC were diagnosed at an
early stage (stages I and II). Among the 146 patients
with TSCC, 134 (92%) underwent partial or hemi-
glossectomy and 12 (8%) underwent total glossec-
tomy. Of the 359 LSCC patients, 82 (21%) received
endoscopic laser excision, 135 (34%) partial laryngec-
tomy, and 175 (45%) total laryngectomy. Moreover,
89 (61%) TSCC and 129 (33%) LSCC patients also
underwent cervical lymph node dissection. Postop-
erative radiation therapy was performed in 29 (20%)
TSCC and 55 (14%) LSCC patients with positive sur-
gical margins, multiple cervical lymph node metastases,
or extracapsular spread in neck pathology.
The definition of SPM was based on the criteria of
Warren and Gates6 as modified by Hong et al in 1990:7
both tumors are malignant with histologic confirma-
tion; the 2 tumors are geographically distinct (at least
2 cm of normal mucosa between them) or separated
in time by 3 or more years; any new tumor of the lung
is solitary and histologically different, unless more than
3 years; and the possibility of metastatic tumor has
been excluded. In terms of chronology, SPMs were
classified as synchronous if they were diagnosed at 
the same time or within 6 months of diagnosis of the
index tumor. After a 6-month follow-up period, they
were defined as metachronous tumors.
All of the patients received a standard follow-up
program, including recent medical history and detailed
head and neck examination every month during the
first year, every 2 months in the second year, every 
3 months in the third year, and every 6 months there-
after. Patients also underwent annual chest radiogra-
phy and necessary investigations, if indicated, by their
symptoms and clinical findings.
Table 1. Patient characteristics (n = 538)
TSCC (n = 146) LSCC (n = 392)
p
n (%) n (%)
Gender < 0.001
Male 121 (83) 378 (96)
Female 25 (17) 14 (4)
Age < 0.001
Range 25–88 35–90
Median 51 68
Risk factors
Tobacco 106 (72) 283 (72) 0.380
Alcohol 53 (36) 63 (16) < 0.001
Betel quid 72 (49) 43 (11) < 0.001
Pathologic T stage < 0.001
T1 52 (36) 104 (27)
T2 65 (45) 120 (31)
T3 20 (14) 85 (22)
T4 9 (6) 83 (21)
Pathologic N stage 0.185
N0 112 (77) 328 (84)
N1 12 (8) 24 (6)
N2 22 (15) 40 (10)
N3 0 (0) 0 (0)
Pathologic TNM stage 0.004
I 49 (34) 102 (26)
II 52 (36) 105 (27)
III 16 (11) 83 (21)
IV 29 (20) 102 (26)
TSCC = squamous cell carcinoma of the tongue; LSCC = squamous cell carcinoma of the larynx.
Statistical analyses were carried out to evaluate the
incidence and characteristics of SPMs in relation to
the site of the index tumor. The χ2 test, Fisher’s exact
test, or Spearman’s rank correlation was used for uni-
variate analysis where appropriate. Associations between
location and patient survival of SPMs were also ana-
lyzed. Survival after SPM development was set as the
time interval from SPM diagnosis to the most recent
follow-up or the patient’s death. Incidence and sur-
vival were calculated using the Kaplan-Meier method.
All analyses were carried out using JMP version 4.0
(SAS Institute Inc., Cary, NC, USA). A p value of less
than 0.05 was considered statistically significant.
Results
Among the 538 patients with TSCC and LSCC, there
were 499 men (93%) and 39 women (7%). The median
age at diagnosis of the index tumor was 51 years (range,
25–88 years) for TSCC and 68 years (range, 35–90
years) for LSCC. The median follow-up time from
surgery for the index tumor was 62 months (range,
1–157 months) for TSCC and 79 months (range,
1–188 months) for LSCC. Between the 2 groups, sta-
tistical differences were found in sex distribution, and
alcohol and betel quid use. A higher proportion of
TSCC patients were alcoholic beverage drinkers (p <
0.001) and betel quid chewers (p < 0.001), while the
percentage of smokers was similar in both groups.
During the follow-up period, the rate of tumor recur-
rence was higher in the TSCC group than in the
LSCC group (33% vs. 22%; p = 0.008). The 5-year
overall survival rates were 66% in TSCC patients and
70% in LSCC patients (p = 0.246).
Characteristics of SPMs in relation to the index
tumor are summarized in Table 2. In the study popu-
lation, SPMs were documented in 77 (14%) patients,
including 18 (12%) in TSCC and 59 (15%) in LSCC
patients. The median time from surgery for the index
tumor to diagnosis of the SPM was 48 months (range,
0–128 months) for TSCC and 59 months (range,
0–162) for LSCC. Thirty-six SPMs (47%) were diag-
nosed beyond 5 years after treatment for the index
tumor. Figure 1 shows the SPM-free survival for patients
with TSCC and LSCC. The incidence of SPM was 3%
per year and was constant during the follow-up period
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Table 2. Characteristics of second primary malignancy in relation to the index tumor
TSCC (n = 146) LSCC (n = 392) p
Incidence 12% (n = 18) 15% (n = 59) 0.320
5-yr SPM rate 10% 11%
10-yr SPM rate 31% 25%
Time interval (mo) 0.436
Median 48 59
Range 0–128 0–162
Synchronous (≤ 6 mo) 12% (n = 2) 10% (n = 6) 0.539
Metachronous (> 6 mo) 88% (n = 16) 90% (n = 53)
Site of SPM 0.017
Head & neck 72% (n = 13) 41% (n = 24)
Non-head & neck 28% (n = 5) 59% (n = 35)
3-yr overall survival 50% 47% 0.652
5-yr overall survival 30% 44%
TSCC = squamous cell carcinoma of the tongue; LSCC = squamous cell carcinoma of the larynx; SPM = second primary malignancy.
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Figure 1. Second primary malignancy-free survival for patients
with index squamous cell carcinoma of the tongue and larynx.
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for at least 10 years. There was no statistically signifi-
cant difference in the incidence of developing SPM
between the 2 groups (p = 0.320).
Table 3 shows the distribution of SPMs. Thirty-
seven SPMs (48%) were carcinomas of the head and
neck region, with the most frequent in the larynx (18%)
and oral cavity (17%). Forty SPMs (52%) were not head
and neck tumors, with the most common sites in the
lung (23%) and esophagus (6%). Cumulative survival
of patients with TSCC and LSCC according to loca-
tion of SPMs is shown in Figure 2. The 5-year overall
survival rate for patients with SPM of the head and
neck was 39%, which was significantly better than that
of non-head and neck SPM patients (29%, p = 0.010).
There was an association between the locations of
index tumor and SPM. Patients with index TSCC had
a higher proportion of SPM within the head and neck
(p = 0.017), with 56% in the oral cavity. On the other
hand, the SPM of patients with index LSCC tended
to be in the respiratory axis, including the lung (31%)
and larynx (24%). After SPM diagnosis, the 5-year
overall survival rates were 30% and 44% in the TSCC
and LSCC groups, respectively (p = 0.651).
Discussion
Since locoregional control of HNSCC has improved
in the past decades, SPM and distant metastasis have
become 2 of the main factors that limit survival.8
More than 80% of distant metastases occur within the
first 2 years after diagnosis of the index HNSCC, and
the incidence decreases with time.9 Conversely, the
incidence of SPM remains constant for an extended
period,1,10 and its development has a long-term effect
on survival. In the present study, SPM increased almost
linearly, with an incidence of 3% per year, compared
to 2–7% in the literature.1,10–12 It is important to
understand the developing pattern of SPMs and provide
appropriate follow-up programs and possible preven-
tion strategies for patients with HNSCC.
The concept of field cancerization has frequently
been used to explain the relatively high incidence of
SPM in patients with HNSCC.13,14 According to this
theory, the respiratory and upper digestive tracts com-
prise a common field that is exposed to a diversity of
carcinogens. The continuous effect of carcinogens on
the entire field results in multiple precancerous changes
that may progress to malignant transformation. Two or
more cancers may develop in the aerodigestive tract.
Several noxious substances, such as alcohol and
tobacco, have been documented to be associated with
a greater risk of SPMs.5,10 In Asians, betel quid chewing
is also a risk factor.15 However, Wiseman et al found
that 25% of head and neck cancer patients without 
Table 3. Distribution of second primary malignancy by index tumor site
TSCC (n = 18) LSCC (n = 59) Total
Site of SPM
n (%) n (%) n (%)
Head & neck 13 (72) 24 (41) 37 (48)
Oral cavity 10 (56) 3 (5) 13 (17)
Oropharynx 1 (6) 1 (2) 2 (3)
Hypopharynx 0 (0) 0 (0) 0 (0)
Larynx 0 (0) 14 (24) 14 (18)
Others 2 (11) 6 (10) 8 (10)
Non-head & neck 5 (28) 35 (59) 40 (52)
Lung 0 (0) 18 (31) 18 (23)
Esophagus 2 (11) 3 (5) 5 (6)
Others 3 (17) 14 (24) 17 (22)
TSCC = squamous cell carcinoma of the tongue; LSCC = squamous cell carcinoma of the larynx; SPM = second primary malignancy.
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Figure 2. Cumulative survival of patients with squamous cell 
carcinoma of the tongue and larynx according to location of the
second primary malignancy (SPM).
a history of smoking and alcohol consumption devel-
oped SPM.16 Therefore, factors such as genetic sensi-
tivity and environmental exposure may also play a role
in the emergence of SPM.17
The distinguishing of a new tumor guides subse-
quent treatment policy and greatly affects prognosis.
Given the similar morphologic appearance, however,
it is not always possible to distinguish between SPM,
local recurrence and distant metastasis using routine
histology techniques. For example, the emergence of
new laryngeal cancer in a patient with previously treated
LSCC will bring up the issue of SPM versus local recur-
rence. Currently, differential diagnosis primarily relies
on clinical parameters, including stage of primary tumor,
disease-free interval, and location of SPM. In this study,
any tumor with a similar histology developing within
2 cm or 3 years of the index tumor was defined as a
local recurrence, and the median interval between the
diagnosis of laryngeal SPM and surgery for LSCC was
67 months (range, 42–155 months). Recent advances
in tumor genetics and molecular biology might offer
better and more scientific diagnostic methods in the
future.13
Consistent with some publications,1,4 the most
common site of SPM in this study was the head and
neck, followed by the lung and esophagus. The distri-
bution also confirms the theory of field cancerization.
Furthermore, the site of the index tumor predicted the
development location of SPM, where TSCC patients
tended to have oral cavity SPMs, while LSCC patients
had SPMs most frequently in the lung and larynx. 
A higher proportion of TSCC patients were also alco-
holic beverage drinkers and/or betel quid chewers,
where the main exposed area is the oral cavity. In con-
trast, the development of LSCC is related to cigarette
smoking.4,10 Although the proportion of smokers was
comparable to that in the TSCC group, more than
half of SPMs of LSCC patients occurred in the respi-
ratory tract. It can be hypothesized that patients with
LSCC might have a higher susceptibility to inhaled
carcinogens, which should be further investigated.
As shown previously, the prognosis of SPM mainly
depends on its location. SPMs occurring outside the
head and neck have a significantly worse prognosis than
those developing in the head and neck. In our study,
the 5-year overall survival rate of second primary lung
cancer was only 20%, and all patients with esophageal
SPM died within 18 months of diagnosis. It is of clin-
ical importance to consider the site of SPM when mak-
ing treatment decisions. Any delay in early and correct
diagnosis is also an important factor that influences
treatment and survival.12 SPMs are frequently not rec-
ognized until they are in a later stage, thereby resulting
in a poorer prognosis. Other factors, including the
patient’s general health condition, remaining treat-
ment choices, and morbidities after previous treatment,
also affect outcome.
Behavioral modification and treatment that can
influence the entire aerodigestive tract may be helpful
in reducing the high incidence of SPM in patients
with HNSCC. Many authors have advocated cessa-
tion of cigarette smoking and alcohol consumption in
the follow-up period.10 To prevent transformation
from a precancerous change to invasive carcinoma,
Sporn et al posited the idea of chemoprevention in
1976.18 Among the drugs administered for inhibiting
carcinogenesis, retinoic acid and its derivatives are the
most widely used. Hong et al reported that daily treat-
ment with high doses of isotretinoin was effective in
preventing SPMs in patients with HNSCC, except for
the drawback of dose-related toxicity.7 However,
Khuri et al found that the occurrence of SPM did not
decrease when treating with low-dose isotretinoin.19
Chemoprevention is still controversial, and further
studies are needed to assess the possible benefits in
HNSCC patients.
HNSCC patients with newly developed SPM may
still have a chance of long-term survival. To diag-
nose SPMs at an earlier stage and achieve higher cure
rates, continuous surveillance is essential.10 However,
Dhooge et al found that 82% of SPMs were diag-
nosed because the patient presented with symptoms.2
Shah and Applebaum also reported that routine annual
chest radiography disclosed only 34% of pulmonary
SPMs and contributed little to the overall survival of
HNSCC patients.20 Therefore, some authors suggest
close follow-up with more frequent chest radiographs,
rather than annually.8 As for routine panendoscopy, the
benefit is not warranted and is often indicated when
the associated symptoms and signs are identified.8
Our data presents a series of patients who were
treated surgically for TSCC and LSCC in a single med-
ical center. Several strengths and limitations should be
noted in this study, and the results should be inter-
preted with caution. First, this study focused on TSCC,
the most common cancer in the oral cavity, because
diverse tumor biology may exist in different subsites of
the oral cavity. Second, positive correlation between
SPM and radiotherapy for the previous tumor has been
reported.3 Investigation of patients primarily treated
with surgery may minimize the influence of radiation
and better represent the actual incidence of SPM in
these patients. In addition, potential drawbacks, includ-
ing the retrospective design and the selection bias in
arranging surgery for treating the index tumor, must
also be noted.
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The clinical significance of this study is in identify-
ing the features of SPMs in patients with TSCC and
LSCC and allowing for a rational follow-up schedule.
By understanding the patterns and distributions of
SPMs, we suggest that patients with previously treated
TSCC and LSCC should receive long-term follow-up.
In addition to standard examinations, TSCC patients
should undergo regular detailed evaluation of the upper
digestive tract, with counseling for frequent oral cav-
ity checking. Patients with LSCC have a higher risk 
of pulmonary SPM and may require more aggressive
chest screening. As an acceptable survival rate can be
achieved, SPMs should be treated with the appropriate
curative therapy.
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